|
Details of the person discharging managerial
responsibilities/person closely associated
|
a)
|
Name:
|
David Gerring
|
2.
|
Reason for the notification
|
a)
|
Position/status:
|
SVP Development
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name:
|
Arecor Therapeutics plc
|
b)
|
LEI:
|
98450093D12I3A8DDD58
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Ordinary shares of 1 pence
each
GB00BMWLM973
|
b)
|
Nature of the
transaction:
|
Grant of options over ordinary
shares
|
c)
|
Price(s) and volume(s):
|
Exercise Price(s) (£)
|
Volume(s)
|
0.01
|
80,000
|
1.585
|
26,000
|
|
d)
|
Aggregated information:
· Aggregated volume:
· Price:
|
106,000
N/A
|
e)
|
Date of the transaction:
|
22 May
2024
|
f)
|
Place of the transaction:
|
Outside of a trading
venue
|
|
|
|
Details of the person discharging managerial
responsibilities/person closely associated
|
a)
|
Name:
|
Sarah Howell
|
2.
|
Reason for the notification
|
a)
|
Position/status:
|
Chief Executive Officer
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name:
|
Arecor Therapeutics plc
|
b)
|
LEI:
|
98450093D12I3A8DDD58
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Ordinary shares of 1 pence
each
GB00BMWLM973
|
b)
|
Nature of the
transaction:
|
Grant of options over ordinary
shares
|
c)
|
Price(s) and volume(s):
|
Exercise Price(s) (£)
|
Volume(s)
|
0.01
|
160,000
|
1.585
|
66,000
|
|
d)
|
Aggregated information:
· Aggregated volume:
· Price:
|
226,000
N/A
|
e)
|
Date of the transaction:
|
22 May
2024
|
f)
|
Place of the transaction:
|
Outside of a trading
venue
|
|
|
|
|
Details of the person discharging managerial
responsibilities/person closely associated
|
a)
|
Name:
|
Manjit Rahelu
|
2.
|
Reason for the notification
|
a)
|
Position/status:
|
Chief Business Officer
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name:
|
Arecor Therapeutics plc
|
b)
|
LEI:
|
98450093D12I3A8DDD58
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Ordinary shares of 1 pence
each
GB00BMWLM973
|
b)
|
Nature of the
transaction:
|
Grant of options over ordinary
shares
|
c)
|
Price(s) and volume(s):
|
Exercise Price(s) (£)
|
Volume(s)
|
0.01
|
60,000
|
1.585
|
13,000
|
|
d)
|
Aggregated information:
· Aggregated volume:
· Price:
|
73,000
N/A
|
e)
|
Date of the transaction:
|
22
May 2024
|
f)
|
Place of the transaction:
|
Outside of a trading
venue
|
|
|
|
Details of the person discharging managerial
responsibilities/person closely associated
|
a)
|
Name:
|
Jan Jezek
|
2.
|
Reason for the notification
|
a)
|
Position/status:
|
Chief Scientific Officer
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name:
|
Arecor Therapeutics plc
|
b)
|
LEI:
|
98450093D12I3A8DDD58
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Ordinary shares of 1 pence
each
GB00BMWLM973
|
b)
|
Nature of the
transaction:
|
Grant of options over ordinary
shares
|
c)
|
Price(s) and volume(s):
|
Exercise Price(s) (£)
|
Volume(s)
|
0.01
|
80,000
|
1.585
|
26,000
|
|
d)
|
Aggregated information:
· Aggregated volume:
· Price:
|
106,000
N/A
|
e)
|
Date of the transaction:
|
22 May
2024
|
f)
|
Place of the transaction:
|
Outside of a trading
venue
|
|
|
|
|
Details of the person discharging managerial
responsibilities/person closely associated
|
a)
|
Name:
|
Helen Parris
|
2.
|
Reason for the notification
|
a)
|
Position/status:
|
SVP Commercial and General Manager,
Tetris Pharma
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name:
|
Arecor Therapeutics plc
|
b)
|
LEI:
|
98450093D12I3A8DDD58
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Ordinary shares of 1 pence
each
GB00BMWLM973
|
b)
|
Nature of the
transaction:
|
Grant of options over ordinary
shares
|
c)
|
Price(s) and volume(s):
|
Exercise Price(s) (£)
|
Volume(s)
|
0.01
|
160,000
|
1.585
|
53,000
|
|
d)
|
Aggregated information:
· Aggregated volume:
· Price:
|
213,000
N/A
|
e)
|
Date of the transaction:
|
22 May
2024
|
f)
|
Place of the transaction:
|
Outside of a trading
venue
|